Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=3&sort=-end_date
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-end_date", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1405&sort=-end_date", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=4&sort=-end_date", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=2&sort=-end_date" }, "data": [ { "type": "Grant", "id": "15762", "attributes": { "award_id": "1K08AI193077-01", "title": "Impact of Spatial and Social Determinants on Invasive Fungal Infection Risk", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 32829, "first_name": "DONA", "last_name": "LOVE", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-08-01", "end_date": "2030-07-31", "award_amount": 197640, "principal_investigator": { "id": 32830, "first_name": "Lucy", "last_name": "Li", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2615, "ror": "", "name": "JOHNS HOPKINS UNIVERSITY", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": ": Invasive fungal infections (IFIs) are a growing public health challenge, leading to over 1.5 million deaths each year worldwide. Contextual factors are believed to be critical components of IFI risk as evidenced by historical fungal outbreaks associated with specific geographic distributions and ecological disruptions. Certain communities are thought to be particularly vulnerable with greater exposure to high-risk contextual factors, leading to higher rates of and worse outcomes from IFIs. In addition, socioeconomic status may impact IFI outcomes, due to delays in diagnosis, access to care, and quality of care. However, prior studies of IFI epidemiology have focused primarily on host factors without adequately considering the uneven distribution of hazards and their spatiotemporal trends related to socioeconomic factors. The objective of this proposal is to assess the impact of social determinants on IFI risk by leveraging a national data source, the National COVID Cohort Collaborative, and a more granular hospital system electronic-health medical records data source. In Aim 1, we will determine neighborhood-level contextual and socioeconomic predictors of IFIs. In Aim 2, we will examine the association between individual socioeconomic status factors and clinical outcomes of IFIs. This work will advance our understanding of the spatial and social determinants of IFI risk and outcomes as well as provide a robust training platform for the award recipient, Dr. Lucy Li. Through both research and career development training, Dr. Li will acquire essential skills in large data analysis, including advanced methods in spatial science and social factors research, time series analyses, and risk prediction modeling. Dr. Li will then be well positioned to be an independent clinical investigator focused on IFIs in at-risk populations with an expertise in integrating spatial and social factors data into population health analyses.", "keywords": [ "Address", "Affect", "Air", "Allergic", "American", "Area", "Asthma", "Award", "COVID-19", "Caring", "Censuses", "Cessation of life", "Clinical", "Clinical Investigator", "Clinical Research", "Communities", "Community Surveys", "Computerized Medical Record", "Data", "Data Analyses", "Data Commons", "Data Sources", "Databases", "Diagnosis", "Dimensions", "Disease", "Disease Outbreaks", "Education", "Electronic Health Record", "Employment Status", "Epidemiology", "Equation", "Ethnic Origin", "Exposure to", "Geographic Distribution", "Geographic Locations", "Health Services Accessibility", "Health system", "Hospitalization", "Hospitals", "Housing", "Immunocompetent", "Immunocompromised Host", "Incidence", "Income", "Individual", "Infection", "Insurance Coverage", "Integration Host Factors", "International Classification of Disease Codes", "Intervention", "Length of Stay", "Logistic Regressions", "Longitudinal trends", "Measures", "Mentors", "Methods", "Molds", "Mycoses", "Neighborhoods", "Organ", "Outcome", "Outcome Assessment", "Patients", "Pattern", "Persons", "Play", "Population", "Populations at Risk", "Positioning Attribute", "Public Health", "Quality of Care", "Race", "Research", "Resolution", "Risk", "Risk Factors", "Science", "Seasons", "Shapes", "Site", "Socioeconomic Factors", "Socioeconomic Status", "Source", "System", "Time Series Analysis", "Training", "United States", "Weather", "Work", "Yeasts", "adjudication", "career", "career development", "clinical care", "clinical risk", "cohort", "contextual factors", "design", "electronic medical record system", "fungus", "hazard", "high risk", "improved", "indexing", "infection risk", "low socioeconomic status", "mortality", "multilevel analysis", "patient screening", "population health", "primary outcome", "research and development", "risk prediction", "risk prediction model", "secondary outcome", "skills", "social determinants", "social factors", "social vulnerability", "socioeconomics", "spatial epidemiology", "spatial integration", "spatial relationship", "spatiotemporal", "statistics", "time use", "trend" ], "approved": true } }, { "type": "Grant", "id": "15769", "attributes": { "award_id": "1K23HL181397-01", "title": "Optimal Ventilator Management in Patients with ARDS on ECMO", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 32586, "first_name": "ROYA", "last_name": "KALANTARI", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-08-01", "end_date": "2030-07-31", "award_amount": 178846, "principal_investigator": { "id": 32840, "first_name": "Mazen Faris", "last_name": "Odish", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2637, "ror": "", "name": "UNIVERSITY OF CALIFORNIA, SAN DIEGO", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Research Plan: Acute respiratory distress syndrome (ARDS) is a severe and common condition that affects 10% of patients in the intensive care unit (ICU), and was a major cause of morbidity and mortality during the COVID-19 pandemic. While mechanical ventilation is often necessary for ARDS, it can also induce additional lung injury known as ventilator induced lung injury (VILI). VILI may be minimized by using low tidal volumes/driving pressure and with positive end expiratory pressure (PEEP). Some patients with severe and refractory ARDS require veno-venous extracorporeal membrane oxygenation (V-V ECMO), the highest level of life support which provides oxygen and removes carbon dioxide from the blood using an external device. A major benefit of ECMO is thought to be the ability to minimize VILI; however, the optimal ventilator settings for patients with ARDS on ECMO are not known. Current guidelines use a one-size-fits-all approach. Our central hypothesis is that personalized PEEP adjusted by measuring intrathoracic pressures via esophageal manometry (Pes) will decease VILI as assessed by biomarkers of inflammation (main outcomes IL-6 and sRAGE). To carry out these aims, we plan to prospectively randomize 62 patients with ARDS on V-V ECMO and neuromuscular blockade and perform serial biomarker measurements with PEEP of 10 cmH2O (ECMO guidelines) vs. PEEP guided by esophageal manometry. In addition to biomarkers of VILI, we will assess differences in other physiological outcomes including pulmonary mechanics and gas exchange. Although this proposal focuses on patients on ECMO, we believe the knowledge gained will have relevance for all patients with ARDS. Career Development Plan: The goal of the PI, Dr. Mazen Odish, is to personalize ARDS and ventilator strategies for those on ECMO based on physiology and biomarkers. The PI has an interest in applied physiology and critical care, this award will help him refine these skills and develop new skills in clinical trials, statistics, and patient-oriented research, to test rigorously methods to care for critically ill patients with ARDS with or without ECMO. To obtain these new skills Dr. Odish and his excellent and multi-disciplinary mentoring/advisory team (led by Drs. Owens and Malhotra, plus outstanding statistical and methodologic support) has three main training goals. 1) Pulmonary mechanics and biomarkers during ARDS, 2) control of breathing and measurement of work of breathing during ARDS/mechanical ventilation, and 3) clinical trial design and statistical training. These training activities are tailored for the PI to achieve his goals and maximize career development towards becoming an independent physician scientist. Furthermore, his structured course work will lead to a Masters of Advanced Studies in Clinical Research. Dr. Odish is at the right place and time in his career to align his clinical expertise in ECMO and ARDS with his research goals to understand optimal ventilator settings and therapies. Eventually his work and new skill set may improve the lives of all people suffering from respiratory illness.", "keywords": [ "Acute Respiratory Distress Syndrome", "Advisory Committees", "Affect", "Arteries", "Atelectasis", "Automobile Driving", "Award", "Biological Markers", "Blood", "Body Weight", "Breathing", "COVID-19 pandemic", "Carbon Dioxide", "Clinical", "Clinical Research", "Clinical Trials", "Clinical Trials Design", "Critical Care", "Critical Illness", "Development Plans", "Devices", "Esophagus", "Extracorporeal Membrane Oxygenation", "Functional disorder", "Gases", "Goals", "Guidelines", "Heart and Lung machine", "Heterogeneity", "Hour", "Hypoxemia", "Induction of neuromuscular blockade", "Inflammation", "Injury", "Intensive Care Units", "Interleukin-6", "Knowledge", "Life", "Lung", "Lung Compliance", "Manometry", "Measurement", "Measures", "Mechanical ventilation", "Mechanics", "Mediator", "Mentors", "Meta-Analysis", "Methodology", "Methods", "Morbidity - disease rate", "Multiple Organ Failure", "Organ", "Outcome", "Oxygen", "Patient Care", "Patients", "Persons", "Physicians", "Physiological", "Physiology", "Positive-Pressure Respiration", "Process", "Prone Position", "Pulmonary Gas Exchange", "Randomized", "Recommendation", "Recording of previous events", "Refractory", "Research", "Research Design", "Resolution", "Respiratory Failure", "Respiratory System", "Respiratory physiology", "Rest", "Risk", "Scientist", "Stress", "Structure", "Testing", "Tidal Volume", "Time", "Training", "Training Activity", "Venous", "Ventilator", "Ventilator-induced lung injury", "Vision", "Work", "Work of Breathing", "career", "career development", "esophagus pressure", "healing", "improved", "improved outcome", "individual patient", "interest", "lung injury", "mortality", "multidisciplinary", "patient oriented research", "personalized approach", "pressure", "prevent", "primary outcome", "prospective", "pulmonary", "radiological imaging", "respiratory", "skills", "soluble RAGE", "statistics", "theories", "ventilation" ], "approved": true } }, { "type": "Grant", "id": "15754", "attributes": { "award_id": "1U01AI186939-01", "title": "Mitigation of multi-organ delayed effects of acute radiation exposure (DEARE) with ACE2 agonist diminazene aceturate.", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 32816, "first_name": "CARMEN I", "last_name": "RIOS", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-08-11", "end_date": "2030-07-31", "award_amount": 546000, "principal_investigator": { "id": 32817, "first_name": "Heather A", "last_name": "Himburg", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2624, "ror": "", "name": "MEDICAL COLLEGE OF WISCONSIN", "address": "", "city": "", "state": "WI", "zip": "", "country": "United States", "approved": true }, "abstract": "With the advent of hematopoietic growth factors for mitigation of acute radiation syndrome (ARS), victims of nuclear or radiological events will be more likely to survive ARS but also at greater risk for the development of a range of late multi-organ toxicities collectively referred to as the delayed effects of acute radiation exposure (DEARE). To date, there are no FDA-approved medical countermeasures (MCMs) for the treatment of DEARE. This application to RFA-AI-23-059 (Development of Candidate Radiation/Nuclear MCMs) proposes to address this unmet need and will focus on the unmet need for MCMs against two life-threatening subsyndromes of DEARE: radiation pneumonitis and nephropathy. Here, we propose to screen three candidate MCMs which target the non-canonical, alternative renin angiotensin system (RAS). As a counterbalance to the canonical RAS, the alternative RAS has broad tissue-protective function by promoting vasodilation, reducing inflammation, and reducing fibrosis. For these reasons, several recent and ongoing clinical trials are evaluating alternative RAS activators for the treatment of severe COVID-19. Data from our lab and others also supports the potential for alternative RAS activation in the treatment of radiation toxicities. Our laboratory has shown diminazene aceturate (DIZE) a small molecule agonist of the alternative RAS pathway promotes survival in rat models of ARS and DEARE. Important to this application, DIZE treatment also mitigated injury to the lung and kidney as evidenced by improved survival during the sub-syndromes of lung and kidney DEARE. Based on these data, we hypothesize the alternative RAS pathway can be targeted pharmacologically to mitigate radiation-induced multi-organ DEARE. Here, we propose a stepwise approach to targeting three key players in the alternative RAS pathway: angiotensin converting enzyme 2 (ACE2), Ang(1-7), and the Mas receptor (MasR). Each Aim of this application will target one of these players using the following lead candidate therapies: DIZE (ACE2 activator), TXA127 (synthetic Ang(1-7)), and BIO101 (MasR activator). We will evaluate the efficacy of the candidate MCMs in an established rat DEARE model which recapitulates the anticipated human sequelae of acute and delayed toxicities. For each candidate MCM, the primary outcome measure will be mitigation of all-cause mortality, which is the clinically relevant endpoint for FDA approval under the Animal Rule.", "keywords": [ "ACE2", "Acceleration", "Acute", "Acute Respiratory Distress Syndrome", "Address", "Adult", "Agonist", "Anti-Inflammatory Agents", "Antiinflammatory Effect", "Antioxidants", "Binding", "Body System", "Bone Marrow", "COVID-19", "Clinical Research", "Clinical Trials", "Data", "Development", "Dose", "Exposure to", "FDA approved", "Fibrosis", "G-Protein-Coupled Receptors", "Generations", "Goals", "Hematopoietic", "Hematopoietic Cell Growth Factors", "Homeostasis", "Human", "Hypoxia", "In Vitro", "Inflammation", "Injury", "Investigation", "Ischemic Stroke", "Kidney", "Kidney Diseases", "Laboratories", "Life", "Lung", "Modeling", "Nuclear", "Nuclear Accidents", "Oral Administration", "Organ", "Outcome Measure", "Pathway interactions", "Peptide Signal Sequences", "Phase I/II Clinical Trial", "Play", "Population", "Radiation", "Radiation Accidents", "Radiation Injuries", "Radiation Pneumonitis", "Radiation Toxicity", "Radiation exposure", "Rattus", "Recovery", "Renin-Angiotensin System", "Reproducibility", "Respiratory Failure", "Risk", "Rodent Model", "Signal Transduction", "Testing", "Therapeutic Uses", "Time", "Tissues", "Toxic effect", "Vasodilation", "Vasodilator Agents", "Work", "animal rule", "clinical investigation", "clinically relevant", "efficacy evaluation", "experience", "improved", "in vivo Model", "irradiation", "lead candidate", "mass casualty", "medical countermeasure", "mortality", "multiorgan injury", "nuclear countermeasure", "pharmacologic", "pre-clinical", "preclinical study", "primary outcome", "programs", "protective effect", "radiation mitigation", "radiation mitigator", "receptor", "response", "severe COVID-19", "small molecule", "stroke patient", "subcutaneous", "therapeutic target" ], "approved": true } }, { "type": "Grant", "id": "15798", "attributes": { "award_id": "1DP2AI192737-01", "title": "Decoding multidrug-resistant pathogen dynamics for clinically-relevant wastewater surveillance", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 32875, "first_name": "INKA I", "last_name": "SASTALLA", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-07-23", "end_date": "2030-06-30", "award_amount": 534000, "principal_investigator": { "id": 32887, "first_name": "Medini K", "last_name": "Annavajhala", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2657, "ror": "", "name": "CHILDREN'S HOSP OF PHILADELPHIA", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "Multidrug-resistant bacteria (MDRB) contribute increasingly to morbidity, mortality, and healthcare costs. Extended-spectrum beta-lactam- and carbapenem-resistant Enterobacterales (ESBL-E and CRE) are MDRB of particular concern due to their demonstrated ability to evolve into highly transmissible clones and acquire and spread antibiotic resistance determinants. Traditional epidemiological surveillance typically focuses on outbreaks of MDRB causing clinical infections, underestimating the burden of these pathogens within hospital systems. Broader efforts that account for asymptomatic carriage and environmental and community reservoirs would be ideal to track and mitigate the spread of MDRB. Wastewater surveillance has proven an effective tool for public health pathogen monitoring, as shown with SARS-CoV-2, but has not been established in clinical settings. This proposal will develop new systems to leverage wastewater for clinically applicable, proactive, and readily deployable MDRB monitoring. In Aim 1, we will establish standardized longitudinal surveillance strategies to inform infection control responses. We will use long-read metagenomics and novel bioinformatic approaches to rapidly identify significant changes in relative or absolute abundance of ESBL-E or CRE compared to site-specific baselines. We will also establish methods to translate wastewater testing data into interpretable “action thresholds” for use by hospital and clinical teams. In Aim 2, we will identify factors enabling the emergence of novel ESBL-E and CRE genotypes in the wastewater environment. Wastewater sampling can identify novel resistant genotypes before detection of clinical infections. We will further develop our novel Metapore-C technique to link bacterial hosts with resistance gene-harboring mobile elements and will use this approach to identify environmental factors such as wastewater antibiotic levels and plumbing design associated with acquisition of resistance. Lastly, in Aim 3 we will devise wastewater testing methodologies suited to resource-limited clinical settings. Given the costs and infrastructure needed for comprehensive clinical surveillance, wastewater testing is better poised to aid in mitigation of MDRB under resource constraints. Yet, current wastewater surveillance approaches are often impractical in such settings. Our strategies for reducing per-sample costs and the analytical burden of wastewater data interpretation, as piloted at a pediatric hospital in Gaborone, Botswana, will serve as a proof-of-concept for wastewater MDRB testing in diverse contexts. Overall, this project will significantly broaden the ability of wastewater surveillance to inform hospital and clinical care efforts, while establishing best practices for global surveillance of antimicrobial resistance in hospital wastewater.", "keywords": [ "2019-nCoV", "Address", "Antibiotic Resistance", "Antibiotics", "Antimicrobial Resistance", "Bacterial Infections", "Bioinformatics", "Biological Testing", "Botswana", "COVID-19 pandemic", "Childhood", "Clinical", "Communities", "Complement", "Data", "Data Analyses", "Detection", "Development", "Disease Outbreaks", "Elements", "Enabling Factors", "Environment", "Environmental Risk Factor", "Epidemiologic Monitoring", "Epidemiology", "Genetic Materials", "Genomics", "Genotype", "Goals", "Health Care Costs", "Health Care Systems", "Horizontal Gene Transfer", "Hospitals", "Infection", "Infection Control", "Infection prevention", "Infrastructure", "Link", "Metagenomics", "Methodology", "Methods", "Mobile Genetic Elements", "Molecular", "Monitor", "Morbidity - disease rate", "Multi-Drug Resistance", "Outcome", "Patients", "Pediatric Hospitals", "Plasmids", "Plumbing", "Population", "Postdoctoral Fellow", "Prevalence", "Protocols documentation", "Public Health", "Research", "Resistance", "Resource-limited setting", "Resources", "Sampling", "Site", "Standardization", "System", "Techniques", "Testing", "Therapeutic", "Thinking", "Translating", "Treatment Failure", "United States", "Work", "beta-Lactams", "bioinformatics pipeline", "carbapenem resistant Enterobacterales", "clinical application", "clinical care", "clinical sequencing", "clinically relevant", "combat", "cost", "cost effective", "design", "experience", "health care settings", "hospital care", "improved", "innovation", "low and middle-income countries", "microbiome", "microbiota", "microorganism", "mortality", "multi-drug resistant bacteria", "multi-drug resistant pathogen", "novel", "pathogen", "resistance gene", "resistance mechanism", "response", "surveillance strategy", "tool", "wastewater sampling", "wastewater surveillance", "wastewater testing" ], "approved": true } }, { "type": "Grant", "id": "15697", "attributes": { "award_id": "1R35GM158174-01", "title": "Multifunctionalized lipid derivatives", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 32560, "first_name": "KADIR", "last_name": "ASLAN", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-07-01", "end_date": "2030-06-30", "award_amount": 394214, "principal_investigator": { "id": 32561, "first_name": "Carsten", "last_name": "Schultz", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 765, "ror": "https://ror.org/009avj582", "name": "Oregon Health & Science University", "address": "", "city": "", "state": "OR", "zip": "", "country": "United States", "approved": true }, "abstract": "It is well understood how lipids are synthesized and metabolized in cells and that many lipids exhibit signalling functions to regulate cellular processes in a spatially and temporally defined way. The latter requires the build- up and turnover of lipid species in membranes either in a site-specific fashion or, alternatively, a directed form of lipid transport. This work aims to investigate the intracellular transfer of lipids from one membrane to another by several proteins that we discovered to be involved in lipid transport. In the previous funding period, we synthesized multifunctional lipid derivatives of five phosphoinositides and four common glycerophospholipids. These feature a photo-activatable protecting group (”cage”) to release the lipid derivative by light and a photo-crosslinking diazirine to covalently attach the lipid derivative to binding proteins. An alkyne group for click chemistry is useful for isolating lipid-protein conjugates or for determining the lipid location in cells by fluorescent tagging and microscopy. In published work, we identified specific lipid binding proteins for phosphatidylinositol 3,4,5-trisphosphate (PIP3), phosphatidylinositol 3,4-bisphosphate [PI(3,4)P2], and phosphatidylinositol (PI) via proteomic analysis. We then used siRNAs to block lipid transport and validated two hits that were required for transporting PIP3 and PI(3,4)P2: cytosolic MPP6 and transmembrane ATP11A. This R35 application proposes the continuation of work described in the application of R01 GM127631, namely the characterization of the lipid transport by the two above mentioned proteins (Project 1). This includes the purification and characterization of recombinant proteins and their functional mutants. We will use purified proteins to determine the 3D structure of MPP6 and its mutants by cryo-electron microscopy with and without crosslinked lipid derivatives. In Project 2, we will synthesize lipid derivatives featuring the photo-crosslinking diazirine closer to the membrane interphase to reach more transiently binding proteins such as those with a PH domain. Comparative proteomic analysis of the lipid interactomes will then be used to identify proteins involved in signalling with and without receptor stimulation. In Project 3, we will use multifunctional lipid derivatives to investigate the lipid interactomes of healthy and virus-infected cells. We recently discovered that an RNA virus infection leads to massive changes in the host cell lipidome. One exciting aspect is that one group of cellular phosphoinositides featuring a particular fatty acid composition is strongly up regulated. We will measure the lipid interactomes of flavivirus- and COVID-infected cells and identify targets crucial for viral infection and replication. Hits will be validated by protein knock-down and the effect on virus infection will be studied. Our unique lipid tools will help to better understand the lipid and lipid binding components of a viral infection.", "keywords": [ "Alkynes", "Binding Proteins", "COVID-19", "Carrier Proteins", "Cell Physiology", "Cells", "Chemistry", "Cryoelectron Microscopy", "Diazomethane", "Exhibits", "Fatty Acids", "Flavivirus", "Funding", "Glycerophospholipids", "Interphase", "Light", "Lipid Binding", "Lipids", "Location", "Measures", "Membrane", "Microscopy", "Modification", "PH Domain", "Phosphatidylinositols", "Proteins", "Proteomics", "Publishing", "RNA Virus Infections", "Recombinant Proteins", "Signal Transduction", "Site", "Small Interfering RNA", "Virus", "Virus Diseases", "Virus Replication", "Work", "comparative", "crosslink", "knock-down", "lipid transport", "lipidome", "mutant", "phosphatidylinositol 3 4 5-triphosphate", "phosphatidylinositol 3 4-diphosphate", "protein purification", "receptor", "three dimensional structure", "tool" ], "approved": true } }, { "type": "Grant", "id": "14974", "attributes": { "award_id": "5R35HL167143-02", "title": "The epigenetic regulation of inflammation in tissue repair and vascular disease", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 24365, "first_name": "Cheryl", "last_name": "McDonald", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-07-01", "end_date": "2030-06-30", "award_amount": 1053460, "principal_investigator": { "id": 21384, "first_name": "Katherine Ann", "last_name": "Gallagher", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 770, "ror": "", "name": "UNIVERSITY OF MICHIGAN AT ANN ARBOR", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true }, "abstract": "The overarching theme for our research program over the past 10 years has been to better understand the etiology and pathogenesis of chronic inflammation in tissue repair processes and vascular disease, with a particular interest in how epigenetics influences the innate immune response and shapes pathologic and homeostatic processes. Our laboratory has contributed seminal studies related to 1) epigenetic regulation of myeloid cells that alter inflammation in abdominal aortic aneurysms (AAA), 2) regulation of macrophage phenotypes by chromatin modifying enzymes (CMEs) during tissue repair, 3) prostaglandin regulation of macrophage plasticity in the setting of tissue repair, 4) chemokines and other signaling pathways driving monocyte recruitment to injured tissue and tissue macrophage phenotypes, 5) epigenetic alterations that impact macrophage function in COVID-19 infection, 6) metabolomic and other biomarker studies in tissue regeneration and cardiovascular disease, 7) role of epigenetic regulation of macrophages following recovery from sepsis. Our work has utilized animal models to carry out mechanistic studies and patient-derived cells and tissues to confirm relevant pathways, identify therapeutic targets and characterize novel biomarkers. Based on our previously published observations and novel preliminary data, our laboratory is broadly focused in 4 main areas. The first serves as a continuation and expansion of HL156274 grant (currently in year 2) to complete and advance therapeutically relevant studies of JMJD3 and other critical CMEs in AAA development. The second goal will serve as renewal of HL137919 and allow us explore JAK/STAT signaling in tissue macrophages and blood monocytes and the downstream regulation of CMEs and subsequent inflammation in a variety of conditions (tissue regeneration, AAAs and post-sepsis recovery). The third goal will be to explore the interactions between structural cells (SMCs, keratinocytes, fibroblasts) and myeloid cells in the setting of tissue regeneration and AAA development. The fourth will be an expansion into the area of peripheral atherosclerosis where we will explore epigenetic regulation of macrophage phenotype/function in the setting of peripheral atherosclerotic disease (PAD). This emerging investigator award (EIA) mechanism will allow us to extend our studies in each of these areas and will allow for mechanistic understanding of the role of epigenetic regulation of macrophage phenotypes in the pathogenesis of a breadth of cardiovascular disease processes including tissue regeneration, aneurysm formation and peripheral atherosclerosis. It will also allow our laboratory to complete proof-of-concept and validation studies needed in both animals and humans to advance new therapies to the clinics for treatment of cardiovascular diseases.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "11717", "attributes": { "award_id": "1R35HL167143-01", "title": "The epigenetic regulation of inflammation in tissue repair and vascular disease", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 24365, "first_name": "Cheryl", "last_name": "McDonald", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-07-01", "end_date": "2030-06-30", "award_amount": 1101440, "principal_investigator": { "id": 21384, "first_name": "Katherine Ann", "last_name": "Gallagher", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 770, "ror": "", "name": "UNIVERSITY OF MICHIGAN AT ANN ARBOR", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true }, "abstract": "The overarching theme for our research program over the past 10 years has been to better understand the etiology and pathogenesis of chronic inflammation in tissue repair processes and vascular disease, with a particular interest in how epigenetics influences the innate immune response and shapes pathologic and homeostatic processes. Our laboratory has contributed seminal studies related to 1) epigenetic regulation of myeloid cells that alter inflammation in abdominal aortic aneurysms (AAA), 2) regulation of macrophage phenotypes by chromatin modifying enzymes (CMEs) during tissue repair, 3) prostaglandin regulation of macrophage plasticity in the setting of tissue repair, 4) chemokines and other signaling pathways driving monocyte recruitment to injured tissue and tissue macrophage phenotypes, 5) epigenetic alterations that impact macrophage function in COVID-19 infection, 6) metabolomic and other biomarker studies in tissue regeneration and cardiovascular disease, 7) role of epigenetic regulation of macrophages following recovery from sepsis. Our work has utilized animal models to carry out mechanistic studies and patient-derived cells and tissues to confirm relevant pathways, identify therapeutic targets and characterize novel biomarkers. Based on our previously published observations and novel preliminary data, our laboratory is broadly focused in 4 main areas. The first serves as a continuation and expansion of HL156274 grant (currently in year 2) to complete and advance therapeutically relevant studies of JMJD3 and other critical CMEs in AAA development. The second goal will serve as renewal of HL137919 and allow us explore JAK/STAT signaling in tissue macrophages and blood monocytes and the downstream regulation of CMEs and subsequent inflammation in a variety of conditions (tissue regeneration, AAAs and post-sepsis recovery). The third goal will be to explore the interactions between structural cells (SMCs, keratinocytes, fibroblasts) and myeloid cells in the setting of tissue regeneration and AAA development. The fourth will be an expansion into the area of peripheral atherosclerosis where we will explore epigenetic regulation of macrophage phenotype/function in the setting of peripheral atherosclerotic disease (PAD). This emerging investigator award (EIA) mechanism will allow us to extend our studies in each of these areas and will allow for mechanistic understanding of the role of epigenetic regulation of macrophage phenotypes in the pathogenesis of a breadth of cardiovascular disease processes including tissue regeneration, aneurysm formation and peripheral atherosclerosis. It will also allow our laboratory to complete proof-of-concept and validation studies needed in both animals and humans to advance new therapies to the clinics for treatment of cardiovascular diseases.", "keywords": [ "Abdominal Aortic Aneurysm", "Aneurysm", "Animal Model", "Animals", "Area", "Atherosclerosis", "Automobile Driving", "Award", "Biological Markers", "Cardiovascular Diseases", "Cells", "Chromatin", "Chronic", "Clinic", "Data", "Development", "Enzymes", "Epigenetic Process", "Etiology", "Fibroblasts", "Goals", "Grant", "Human", "Inflammation", "Innate Immune Response", "Laboratories", "Myeloid Cells", "Pathogenesis", "Pathologic", "Pathway interactions", "Patients", "Peripheral", "Phenotype", "Process", "Prostaglandins", "Publishing", "Recovery", "Regulation", "Research", "Research Personnel", "Role", "SARS-CoV-2 infection", "Seminal", "Sepsis", "Shapes", "Signal Pathway", "Signal Transduction", "Smooth Muscle Myocytes", "Therapeutic", "Tissues", "Vascular Diseases", "Work", "chemokine", "coronavirus disease", "epigenetic regulation", "immunoregulation", "injured", "interest", "keratinocyte", "macrophage", "metabolomics", "monocyte", "novel", "novel marker", "novel therapeutics", "programs", "recruit", "therapeutic target", "tissue injury", "tissue regeneration", "tissue repair", "validation studies" ], "approved": true } }, { "type": "Grant", "id": "15777", "attributes": { "award_id": "1R01AR085033-01", "title": "Improving the diagnosis and outcome of diffuse alveolar hemorrhage in systemic lupus erythematosus", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 32850, "first_name": "MARIE", "last_name": "MANCINI", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-08-06", "end_date": "2030-06-30", "award_amount": 538755, "principal_investigator": { "id": 32851, "first_name": "WESTLEY H", "last_name": "REEVES", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 32852, "first_name": "Haoyang", "last_name": "Zhuang", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 2642, "ror": "", "name": "UNIVERSITY OF FLORIDA", "address": "", "city": "", "state": "FL", "zip": "", "country": "United States", "approved": true }, "abstract": "The variable clinical manifestations of SLE patients are largely unexplained. Although severe diffuse alveolar hemorrhage (DAH) with pulmonary capillaritis is unusual in lupus, more than half of patients with this complication die and focal lung hemorrhage occurs in 30-66% of patients. Using a mouse model (pristane-induced lupus) developed in our laboratory, we will ask why C57BL/6 (B6) mice are susceptible to pristane-induced DAH/vasculitis whereas BALB/c and DBA/2 mice are resistant. DAH is initiated by lung endothelial cell (EC) injury followed by recruitment of bone marrow-derived monocytes to the lung. We found that dysregulation of the extrinsic coagulation pathway also is involved and that lung disease is abolished by early treatment with MEK1/2 or ERK1/2 inhibitors. The overall hypothesis is that genetically- determined lung microvascular EC injury evolves into DAH because of monocyte infiltration into the lung and abnormal regulation of the extrinsic coagulation pathway. Aim 1 addresses susceptibility to DAH. We will ask whether EC injury and bleeding are lung-specific and investigate gene expression patterns associated with DAH by single-cell RNA-sequencing. Genes conferring susceptibility/resistance to EC injury and bleeding be mapped in recombinant inbred BXD (B6 X D2) mice. Aim 2 examines the MEK1/2-ERK1/2 pathway in pristane-induced DAH. We will define the sequence of events leading to DAH and develop blood-based diagnostic tests for the diagnosis of incipient DAH prior to the onset of bleeding. This is important, because the disease process is irreversible once hemorrhage begins. We will look for tests that distinguish early DAH (pre-bleeding) from other forms of lung injury, such as sepsis with acute respiratory distress syndrome. Aim 3 translates what is learned in mice to human DAH. We hypothesize that the disease process is similar except that the initial EC injury is caused by respiratory viral infections rather than pristane. We will ask if a predisposition to lung EC injury determines susceptibility, as in mice, and whether diagnostic approaches developed in the mouse model are relevant to human DAH. Lung EC injury will be examined in SLE patients with influenza or COVID infection and the role of mild bleeding disorders will be explored. The ability to diagnose incipient DAH (pre- bleeding) may permit future therapeutic trials using FDA-approved MEK1/2 inhibitors, such as trametinib, which are highly effective in pristane-induced DAH.", "keywords": [ "ANCA vasculitis", "Acute Respiratory Distress Syndrome", "Address", "Adopted", "Alveolar", "Antineutrophil Cytoplasmic Antibodies", "Autoantibodies", "Autoimmune", "Autoimmune Diseases", "BALB/cJ Mouse", "Biological Assay", "Blood", "Blood Coagulation Disorders", "Blood Vessels", "Bone Marrow", "C57BL/6 Mouse", "COPA syndrome", "Cell Line", "Clinical", "Coagulation Process", "Complex", "Complication", "DBA/2 Mouse", "Data", "Defect", "Dependence", "Development", "Diagnosis", "Diagnostic tests", "Diffuse", "Disease", "Disease susceptibility", "Early Diagnosis", "Early treatment", "Endothelial Cells", "Environmental Risk Factor", "Enzyme-Linked Immunosorbent Assay", "Event", "Exanthema", "Exhibits", "FDA approved", "Future", "Gene Expression", "Gene Expression Profile", "Genes", "Genetic", "Genetic Predisposition to Disease", "Hemorrhage", "Hemostatic function", "Human", "Immune", "Immunologics", "Inbred BALB C Mice", "Inbreeding", "Infiltration", "Inflammation", "Inherited", "Injury", "Intervention", "Kidney", "Laboratories", "Learning", "Life", "Link", "Lung", "Lung Diseases", "Lupus", "Lupus Nephritis", "MAP2K1 gene", "MAPK3 gene", "Malignant Neoplasms", "Maps", "Mediating", "Mitogen-Activated Protein Kinases", "Modeling", "Monitor", "Mouse Strains", "Mus", "NUP214 gene", "Outcome", "Pathogenesis", "Pathway interactions", "Patients", "Plasma", "Predisposition", "Pristane", "Process", "Prognosis", "Public Health", "Qualifying", "Recombinants", "Regulation", "Resistance", "Respiratory Tract Infections", "Retinal blind spot", "Role", "SARS-CoV-2 infection", "Sepsis", "Serum", "Severity of illness", "Systemic Lupus Erythematosus", "Testing", "Therapeutic Trials", "Tissues", "Translating", "Vascular Diseases", "Vasculitis", "Viral Respiratory Tract Infection", "cell injury", "diagnostic strategy", "ds-DNA", "experience", "genome wide association study", "immune function", "improved", "influenza infection", "inhibitor", "injured", "lung injury", "lung microvascular endothelial cells", "monocyte", "mouse model", "novel therapeutics", "prevent", "protein expression", "pulmonary", "recruit", "sepsis induced ARDS", "single-cell RNA sequencing", "treatment response" ], "approved": true } }, { "type": "Grant", "id": "15767", "attributes": { "award_id": "1R35GM160163-01", "title": "Scalable and Epidemiologically Interpretable Phylodynamics to Recover Heterogeneous Transmission Dynamics", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 32565, "first_name": "GUOQIN", "last_name": "YU", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-08-01", "end_date": "2030-06-30", "award_amount": 410000, "principal_investigator": { "id": 32838, "first_name": "Nicola Felix", "last_name": "Mueller", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2635, "ror": "", "name": "UNIVERSITY OF CALIFORNIA, SAN FRANCISCO", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "As pathogens are transmitted between individuals, they accumulate mutations, leaving a footprint of the transmission history in the pathogen genomes. Using phylogenetic methods, we can reconstruct the transmission history connecting individual cases from these genomes, by reconstructing the relationships of the pathogens. We can then infer population-level transmission dynamics, from the ancestral relationships of the pathogens, or phylogenies, using phylodynamic methods. Infectious disease transmission and disease burden are highly heterogeneous, differing between neighborhoods, across age, and socioeconomic groups, and racial and ethnic lines. This heterogeneity means that it is crucial to a) be able to illuminate differential disease burdens and b) account for these heterogeneities when modeling or forecasting infectious disease outbreaks. Traditional approaches based on reported caseloads are often insufficient for capturing the full scope of highly heterogeneous transmission dynamics. Phylodynamics offers a potential solution, as it infers transmission dynamics from the connectivity of cases, providing an opportunity to disentangle these complex patterns. However, limitations in our available toolbox prevent us from fully utilizing the vast availability of pathogen genomes to study these complex transmission dynamics, as current phylodynamic approaches suffer from multiple challenges. With the advent of widely available sequencing, phylodynamic tools are not computationally efficient enough to analyze the amounts of data generated at the granular scales crucial to understanding transmission dynamics. Additionally, the model parameters need to be epidemiologically interpretable to be actionable. In this project, we seek to address these two points by developing novel approaches to reconstruct transmission dynamics from pathogen sequence data. We will develop novel phylodynamic tools to reconstruct transmission dynamics at a granular scale by integrating neural networks into phylodynamic likelihood calculations that we show in preliminary results to dramatically improve computational efficiency and scalability. Phylodynamic methods are parameterized by more or less abstract parameters that either have no direct epidemiological meaning or are contingent on idealized assumptions about disease spread. We will establish how and when current approaches return biased results when reconstructing city-scale transmission dynamics, describe how they can be used to estimate actual disease burden, and test them using SARS-CoV-2 sequence data collected by Kaiser Permanente Southern California (KPSC) and in the UK over the pandemic. Finally, we will develop ways to quantify the factors influencing disease burden, such as geography, age, and socioeconomics. We will apply these tools to KPSC SARS-CoV-2 data, where we can access rich patient metadata to study these patterns. Our overarching goal is to utilize phylodynamic inference of heterogeneous transmission dynamics to parameterize complex infectious disease dynamic models and improve prediction accuracy.", "keywords": [ "2019-nCoV", "Address", "Age", "California", "Cities", "Communicable Diseases", "Complex", "Data", "Disease", "Disease Outbreaks", "Epidemiology", "Ethnic Origin", "Genome", "Geography", "Goals", "Guidelines", "Heterogeneity", "Individual", "Metadata", "Methods", "Modeling", "Mutation", "Neighborhoods", "Patients", "Pattern", "Phylogenetic Analysis", "Phylogeny", "Population", "Race", "Recording of previous events", "Reporting", "Testing", "Viral", "burden of illness", "disease transmission", "genome sequencing", "improved", "neural network", "novel", "novel strategies", "pandemic disease", "pathogen", "pathogen genome", "prevent", "socioeconomics", "tool", "transmission process" ], "approved": true } }, { "type": "Grant", "id": "15805", "attributes": { "award_id": "1K01DA062904-01", "title": "Clinician cannabis use-related preconceptions perpetuating low quality of prenatal care for women who use cannabis during pregnancy", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Drug Abuse (NIDA)" ], "program_reference_codes": [], "program_officials": [ { "id": 32896, "first_name": "SARAH", "last_name": "VIDAL", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-07-15", "end_date": "2030-06-30", "award_amount": 196236, "principal_investigator": { "id": 32897, "first_name": "Rachel Carmen", "last_name": "Ceasar", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2622, "ror": "", "name": "UNIVERSITY OF SOUTHERN CALIFORNIA", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Cannabis is the most used illicit substance during pregnancy. Rates of self-medicating with cannabis escalated during the COVID-19 pandemic. The scientific objective of this proposal is to investigate the mechanisms contributing to preconceptions about those who use cannabis, especially during pregnancy. The central hypothesis is that preconceptions about those who use cannabis result in negative interactions between patients and clinicians that reduce the quality of healthcare and result in poor outcomes. This innovative project will be the first to: (a) leverage natural language processing/artificial intelligence (NLP/AI) techniques to investigate preconceptions about cannabis use in clinical notes, and (b) investigate associations between cannabis use and prenatal care quality. Research aims will: (Aim 1) Investigate preconceptions about those who use cannabis during pregnancy using a mixed methods approach that integrates NLP/AI and qualitative interviews; (Aim 2) Investigate associations between cannabis use and prenatal care quality among different population groups, such as differences in socioeconomic status and education levels; and (Aim 3) Develop, adapt, and test the feasibility and usability of a clinician training on quality health care practices for those who use cannabis during pregnancy using a multistage modified Delphi process, survey, and qualitative focus groups. This research is complemented by a training plan that builds upon Dr. Rachel Carmen Ceasar’s background in mixed qualitative-quantitative methods and substance use research. The training plan includes using NLP/AI approaches, advanced survey methods in reproductive epidemiology, and implementation science. Together, this research and training will prepare Dr. Ceasar to advance as an independent investigator conducting research on health and substance use among those who are pregnant across the lifespan. The proposed project will improve clinicians’ care of those who use cannabis during pregnancy, providing evidence to inform the development of interventions designed to reduce cannabis-use-related notions in prenatal care.", "keywords": [ "Adverse effects", "American College of Obstetricians and Gynecologists", "Artificial Intelligence", "Belief", "COVID-19 pandemic", "California", "Cannabis", "Caring", "Child Welfare", "Clinical", "Clinical Treatment", "Consensus", "Cross-Sectional Studies", "Data", "Detection", "Education", "Educational Status", "Family", "Focus Groups", "Fright", "Future", "Goals", "Guidelines", "Gynecologic", "Health", "Health Benefit", "Health Care", "Income", "Infant", "Interview", "Knowledge", "Language", "Legal", "Link", "Los Angeles", "Medical", "Medical center", "Mentored Research Scientist Development Award", "Mentors", "Methods", "Modeling", "Moods", "Mothers", "Natural Language Processing", "Nausea", "Outcome", "Output", "Pain", "Patient Outcomes Assessments", "Patients", "Persons", "Policies", "Policy Maker", "Population", "Population Group", "Pregnancy", "Pregnancy Outcome", "Pregnant Women", "Prenatal care", "Prevalence", "Process", "Quality of Care", "Questionnaires", "Recommendation", "Reporting", "Research", "Research Personnel", "Rice", "Risk", "Socioeconomic Status", "Supervision", "Survey Methodology", "Surveys", "Techniques", "Testing", "Time", "Training", "Woman", "authority", "cannabis cessation", "comparative", "efficacy evaluation", "evidence base", "experience", "feasibility testing", "follow-up", "health care delivery", "health care quality", "implementation science", "improved", "indexing", "innovation", "large language model", "life span", "low socioeconomic status", "marijuana use", "marijuana use in pregnancy", "neurodevelopment", "open source", "preconception", "prenatal", "provider behavior", "reproductive epidemiology", "substance use", "therapy design", "therapy development", "usability" ], "approved": true } } ], "meta": { "pagination": { "page": 3, "pages": 1405, "count": 14046 } } }